{Reference Type}: Journal Article
{Title}: Clinical role of serum microRNA-155 in early diagnosis and prognosis of septic patients with acute kidney injury.
{Author}: Fan H;Sun M;Zhu JH;
{Journal}: Int Urol Nephrol
{Volume}: 56
{Issue}: 5
{Year}: 2024 May 28
{Factor}: 2.266
{DOI}: 10.1007/s11255-023-03855-z
{Abstract}: <B>OBJECTIVE: </B>Acute kidney injury (AKI) is a common complication in patients with sepsis, and early detection and timely treatment are crucial. This article aims to explore the clinical role of microRNA-155 (miR-155) in early diagnosis and prognosis evaluation of septic patients with acute kidney injury.<BR><B>METHODS: </B>We collected the blood samples of septic patients and measured the relative expression of serum miR-155 by RT-qPCR, and drew the receiver operating characteristic (ROC) curves to evaluate its early diagnosis for septic AKI.<BR><B>RESULTS: </B>The relative expression of miR-155 in the septic AKI was significantly higher than that in the septic non-AKI, and increased with the aggravation of renal function damage. The ROC curve of miR-155 for the diagnosis of septic AKI was 1.91 (95% CI: 1.61-2.19). When the optimal cut-off value of miR-155 expression was 2.37, its sensitivity for diagnosing septic AKI was 91.12% (95% CI: 80.41-95.07%), and its specificity was 84.52% (95% CI: 71.74-89.36%). Furthermore, the severity of kidney injury, SOFA score, APACHE II score and miR-155 were the risk factors affecting the prognosis of septic patients with AKI.<BR><B>CONCLUSIONS: </B>Serum miR-155 can be used as a novel biomarker for the early diagnosis of septic AKI, and also has important clinical value in the prognosis evaluation of septic patients with AKI.